ReviewBritish journal of pharmacology2018
Mirabegron: potential off target effects and uses beyond the bladder.
Review in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Efficacy of novel βInternational journal of urology : official journal of the Japanese Urological Association · 2019Trial
- Reexamining Fat: Exploring Diversity, Plasticity, Development, Functional Implication, and Therapeutic Options.International journal of molecular sciences · 2026Review
- Tadalafil Ameliorates Chronic Ischemia-Associated Bladder Overactivity in Fructose-Fed Rats by Exerting Pelvic Angiogenesis and Enhancing p-eNOS Expression.International journal of molecular sciences · 2025Article
- The thermogenic effect of mirabegron ingestion during cool conditions.Frontiers in physiology · 2025Article
- Mirabegron for intramural ureteral stones with vesical irritability: a prospective study.Frontiers in pharmacology · 2025Article
- Is the βBiomolecules · 2023Review
- Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug.Journal of clinical medicine · 2023Review
- Article
- Article
- Inhibition of prejunctional parasympathetic pathways by βFrontiers in pharmacology · 2023Article
- β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition.Cardiovascular diagnosis and therapy · 2022Article
- Mirabegron Ameliorated Atherosclerosis of ApoECardiovascular drugs and therapy · 2022Article
- Pharmacophore-guided Virtual Screening to Identify New βMolecular informatics · 2022Article
- Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy.Endocrine reviews · 2022Review
- Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.International journal of molecular sciences · 2022Article
- The novel anti-colitic effect of β-adrenergic receptorsFrontiers in pharmacology · 2022Article
- Effects of β3-adrenoceptor agonist on acute urinary retention in a rat model.World journal of urology · 2021Article
- Effects of Caffeine on Brown Adipose Tissue Thermogenesis and Metabolic Homeostasis: A Review.Frontiers in neuroscience · 2021Review
- Concentration-dependent alphaFrontiers in pharmacology · 2021Article
- The metabolic effects of mirabegron are mediated primarily by βPharmacology research & perspectives · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The β LINKED ARTICLES: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.21/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.